|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Colorectal Cancer | |||||
| Metastatic Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Colorectal Neoplasms | |||||
| Neoplasm Metastasis | |||||
| 3 | More general conditions related to this trial | ||||
| Colonic Diseases | |||||
| Digestive System Diseases | |||||
| Digestive System Neoplasms | |||||
| Gastrointestinal Diseases | |||||
| Gastrointestinal Neoplasms | |||||
| Intestinal Diseases | |||||
| Intestinal Neoplasms | |||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| Neoplastic Processes | |||||
| Pathologic Processes | |||||
| Rectal Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| floxuridine | |||||
| fluorouracil | |||||
| conventional surgery | |||||
| radiofrequency ablation | |||||
| 5 | More general drug interventions related to this trial | ||||
| Antimetabolites | |||||
| Antimetabolites, Antineoplastic | |||||
| Antineoplastic Agents | |||||
| Immunologic Factors | |||||
| Immunosuppressive Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| M.D. Anderson Cancer Center | |||||
| National Cancer Institute (NCI) | |||||